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Vif forms a complex with Elongin B/C, Cullin-5 and Rbx-1 to induce the polyubiquitination and proteasome-mediated degradation of human
APOBEC3G (hA3G). These interactions serve as potential targets for anti-HIV-1 drug development. We have developed a cell culture-based assay
to measure Vif-induced hA3G degradation. The assay is based on α-complementation, the ability of β-galactosidase fragments to complement in
trans. hA3G expressed with a fused α-peptide was enzymatically active, complemented a coexpressed ω-fragment and could be targeted for
degradation by Vif. Vif reduced β-galactosidase activity in the cell by 10–30-fold. The assay was validated by testing various hA3G and Vif point
mutants. The assay accurately detected the effects of D128 in hA3G, and the BC box, Cul5 box and HCCH motifs of Vif. The results showed a
strict association of Vif biological function with hA3G degradation. These findings support hA3G degradation as a requirement for Vif function.
The Vif α-complementation assay may be a useful tool for the identification of Vif inhibitors.
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APOBEC3 cytidine deaminases constitute an arm of the
innate immune system that protects against HIV-1 and the
transposition of endogenous retroelements (Cullen, 2006; Harris
and Liddament, 2004; Navarro and Landau, 2004). In HIV-1 that
is deleted for Vif (Δvif ), human APOBEC3G (hA3G) as well as
other APOBEC3 family members can be packaged into virions
in an infected cell. In the next round of replication, the packaged
hA3G deaminates the viral DNA as it is synthesized. C→U
deamination of the viral DNA minus-strand is manifested as
G→A hypermutation of the plus-strand. Wild-type HIV-1
encodes the accessory protein Vif, which binds APOBEC3G and
APOBEC3F to induce their rapid proteasomal degradation prior
to encapsidation.
To cause hA3G degradation, Vif associates with a specific
ECS-type E3 ligase which consists of Cullin-5 (Cul5), Elongin
B, Elongin C and Rbx1 subunits (Mehle et al., 2004a; Yu et al.,
2003). The Vif/Elongin BC/Cul5 complex catalyzes polyubi-⁎ Corresponding author. Fax: +1 858 554 0341.
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doi:10.1016/j.virol.2006.09.013quitination of A3G which is followed by proteasomal degrada-
tion. Association of the E3 ligase with Vif is mediated by a
sequence motif homologous to that of SOCS-box proteins, a
family of proteins that mediates the binding of substrate to the E3
ligase. The SLQ sequence in Vif is highly conserved and has
homology to the SOCS box motif (Marin et al., 2003; Mehle et
al., 2004a; Yu et al., 2004). An HCCHmotif in primate lentiviral
Vif is required for Vif interaction with Cul5, but not with Elongin
B or Elongin C (Luo et al., 2005).
We report here on the development of a cell-based assay to
measure Vif-induced hA3G degradation. The assay is based on
α-complementation of β-galactosidase in which an 84 amino
acid, amino-terminal α-fragment of β-galactosidase and a
carboxy-terminalω-fragment, associate to form the catalytically
active tetrameric enzyme. The method was validated by testing
A3G and Vif mutations that are involved in Vif-induced A3G
degradation. This assay can be easily adapted to a high-
throughput format and used to perform large-scale screening for
small chemical molecules that interrupt Vif-induced hA3G
degradation. Various Vif and hA3G molecules that contained
missense amino acid changes in conserved amino acid motifs
were tested for α-complementation, biological function and
Fig. 1. hA3G-α complements ω-fragment in transfected cells. 293T or 293T-ω
cells were transfected with pA3G-α in triplicate. After two days, lysates were
prepared and normalized for protein and β-galactosidase activity was measured
by luminescence. The results are shown with the standard deviation.
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association of hA3G degradation with Vif biological function,
strongly supporting degradation of hA3G as a requirement for
Vif function.
Results
We previously reported on an α-complementation assay to
measure viral envelope glycoprotein-mediated fusion (Holland
et al., 2004). In that assay, the α-fragment and envelope
glycoprotein were expressed in one cell and the ω-fragment and
CD4/coreceptor in another. Upon co-culture of the cells,
envelope glycoprotein-mediated fusion caused mixing of the
cells' cytoplasm, resulting in α-complementation. β-galactosi-
dase activity could then be measured rapidly and accurately
using luminescent substrate.
To establish an assay to measure Vif induced degradation of
A3G, we adapted the α-complementation fusion assay (Holland
et al., 2004). An hA3G-α fusion protein was expressed in cells
that stably express the ω-fragment. α-complementation of the
hA3G-α and the ω-fragment was predicted to generate high
levels of β-galactosidase. In addition, the activity would be
reduced by Vif as a result of the proteasomal degradation of the
hA3G-α. The amount of β-galactosidase activity in the cells
with and without Vif would be a measure of Vif-induced A3G
degradation.
For the assay, the vector pA3G-α was constructed that
expressed hA3G with the α-peptide fused to the C-terminus. To
test whether hA3G-α was competent to mediate α-complemen-
tation, 293T and 293T-ω cells were transfected with pA3G-α
plasmid alone or with pCMV-ω. As negative controls, the cells
were transfected separately with pCMV-α and pCMV-ω. As
positive controls, the cells were either cotransfectedwith pCMV-
α and pCMV-ω or transfected with pCMV-LacZ which encodes
full-length β-galactosidase. pCMV-α, pA3G-α and hA3G
without the fused α-peptide (data not shown) yielded back-
ground levels of β-galactosidase activity (Fig. 1). Cotransfec-
tion of pA3G-α and pCMV-ω resulted in a high level of
βQgalactosidase activity, yielding a signal that was more than
100-fold above background and nearly as high as the native
βQgalactosidase. As the amount of transfected pA3G-α was
increased, the enzyme activity levels increased further. The
amount of β-galactosidase activity generated was similar in
293T-ω cells, suggesting that ω-fragment expression was not
limiting (Fig. 1). These results showed that hA3G-α efficiently
complemented the ω-fragment in the transfected cells.
Next, we tested whether hA3G-α maintained antiviral
function. This was tested using single-cycle wild-type and Δvif
luciferase reporter viruses. To produce the reporter viruses,
293T cells were cotransfected with wild-type or Δvif pNL-
LucE−R− and either pA3G-α or control HA-tagged hA3G
expression vector. pA3G-α was found to reduce virus
infectivity to an extent comparable to hA3G and was found
to be sensitive to Vif (Fig. 2A). These results suggested hA3G-
α to be fully competent to be packaged into virions and to bind
to Vif. Immunoblot analysis of the cell lysates showed that the
hA3G-α was present at reduced quantity in cells that expressedVif (Fig. 2B). The reaction was comparable to that of HA-
tagged hA3G. Thus, the hA3G-α maintained the properties of
the native protein.
To determine how effectively Vif would reduce α-comple-
mentation, 293T-ω cells were transfected with pA3G-α, with
or without HIV-1 Vif expression vector. Two days later,
βQgalactosidase activity was measured. In the absence of Vif,
increasing amounts of hA3G-α expression vector caused
corresponding increases in β-galactosidase activity levels (Fig.
3A). Vif caused a 10-fold decrease in β-galactosidase activity
and this reduction was maintained over a range of hA3G-α
expression levels. Immunoblot analysis of the cell lysates
showed that Vif had caused a reduction of hA3G-α to
undetectable levels (Fig. 3B). This was the case even in the
transfection with the least amount of hA3G-α. As hA3G was
increased, Vif decreased. This result confirmed the earlier
findings of Mehle et al. (2004b) that Vif is degraded with
hA3GQα. Thus, the α-complementation assay accurately
reflected hA3G levels and was more sensitive and quantitative
than immunoblot analysis.
β-galactosidase activity can also be measured colorimetri-
cally using ONPG substrate, which is less expensive and
produces a stable signal. To determine whether this method was
suitable for the α-complementation assay, cell lysates from the
previous experiment were incubated with ONPG and read at
time points from 10–120 min. The signal increased over 60 min
and then reached a plateau (Fig. 3C). The measurements agreed
with the luminescent substrate results, also showing the 10-fold
decrease in signal caused by Vif.
Several Vif expression vectors were tested for efficiency of
hA3G-α degradation. phVif (Nguyen et al., 2004) and phVifLF
express a partially codon-optimized HIV-1 Vif in pcDNA3.1-
Myc-His and pcDNA3.1, respectively. pcVif(co)-HA and pcVif
(co) express a fully codon optimized HIV-1 Vif with or without a
C-terminal HA tag (Schrofelbauer et al., 2006). The Vif
expression vectors were tested in the α-complementation
assay. The fully codon-optimized Vifs were more efficient,
reducing β-galactosidase activity 20–30-fold (Fig. 4).
Fig. 2. hA3G-α maintains antiviral function. (A) Antiviral activity was
measured with single-cycle HIV luciferase reporter virus. Reporter viruses
were prepared in 293T cells cotransfected with wild-type or Δvif NL-Luc and
A3G expression vector. Infectivity of the viruses was tested by infection of HOS
cells and measurement of intracellular luciferase activity 3 days postinfection.
(B) hA3G-α in the transfected cells was detected on an immunoblot of cell
lysates probed with anti-A3G mAb.
Fig. 3. Measurement Vif function by α-complementation. (A) 293T-ω cells were
transfected with pA3G-α alone (0.16, 0.4, 0.7, or 1.0 μg) or cotransfected with
Vif expression vector (4 μg). β-galactosidase activity was measured 2 days later
by luminescence. (B) Quantitation of Vif-induced hA3G-α degradation by
immunoblot analysis. (C) β-galactosidase activity in the α-complementation
assay was determined by colorimetric analysis with ONPG substrate. Cell
lysates were prepared in triplicate and normalized for protein concentration.
ONPG substrate was added and A405 was measured over time.
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the interaction with Vif (Bogerd et al., 2004; Mangeat et al.,
2004; Schrofelbauer et al., 2004; Xu et al., 2004). To test
whether the D128K mutant, which contains the African green
monkey-specific amino acid residue, was associated with
resistance to Vif induced degradation, the mutation was
introduced into hA3G-α and tested in the α-complementation
assay. Over a range of hA3G-α concentrations, hA3G D128K-α
was largely resistant to Vif (Fig. 5A). β-galactosidase was
slightly reduced by the D128K mutant, indicating that it is still
slightly sensitive to HIV-1 Vif. Luciferase reporter virus assay
confirmed that the hA3G D128K-α was functional (Fig. 5B).
The effect of Vif on the steady state level of D128K hA3G-α
was tested by immunoblot analysis. This showed what appeared
to be a more substantial degradation of hA3G D128K-α by Vif
than what was detected by α-complementation (Fig. 5C). Thus,
the D128K hA3G molecules that escape Vif degradation are
sufficient to block viral infectivity. The α-complementation
assay more accurately represents the antiviral function of Vif
than does the immunoblot. These results further support an
association of A3G degradation with Vif function.
Amino acid motifs of Vif that are required for Vif function
include a BC-box that has similarity to the SOCS6 motif
(SLQ144–146), a Cul5-box (L163P164L169) (Mehle et al.,
2004a; Shirakawa et al., 2006; Yu et al., 2004) and an HCCH
motif (Luo et al., 2005). To determine whether the role of these
motifs could be detected in the α-complementation assay, the
mutations were introduced into codon-optimized Vif and themutants were tested in the assay. As shown in Fig. 6A, the BC-
box triple SLQ→AAA mutation abolished Vif function in the
assay although single amino acid changes in the motif did not
affect Vif function. Single amino acid mutations in the HCCH
motif abolished Vif function. These effects were confirmed by
immunoblot analysis, which showed that the mutations that
blocked Vif function in the α-complementation assay failed to
induce hA3G-α degradation. Analysis of the mutants in the
luciferase reporter virus assay showed that the α-complemen-
tation assay accurately determined Vif function in the virus. The
SLQ triple mutant and the HCCH single mutants were
nonfunctional in both assays (Fig. 6A, top and bottom).
Analysis of mutants in the Cul5-box showed that the triple
mutation (L163AP164AL169A) was inactive. A single muta-
tion in the Cul5-box at amino acid 163 was still active while the
Fig. 4. Comparison of Vif expression vectors in the α-complementation assay.
293T-ω cells were cotransfected with 4 μg of Vif expression vectors phVifLF,
phVif, pcVif(co)-HA or pcVif(co) and with or without pA3G-α (0.1, 0.2 or
0.5 μg).
Fig. 5. α-Complementation accurately detects the effect of the D128K mutation
on hA3G degradation. (A) 293T-ω cells were transfected with wild-type A3G-α
or A3G-α D128K with or without pcVif(co) and β-galactosidase was measured
after 2 days. (B) Analysis of D128K hA3G-α antiviral activity by luciferase
reporter virus assay. 293T cells were cotransfected with wild-type or Δvif
NLQLuc with wild-type A3G-α or A3G-α D128K. Virus was harvested,
normalized for p24 and measured for infectivity in HOS cells. (C) Immunoblot
analysis of the effect of Vif on steady-state levels of D128K A3G-α. Transfected
cell lysates were probed with anti-A3G mAb.
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Immunoblot analysis confirmed that these mutations were
active at the level of hA3G degradation. Luciferase reporter
virus analysis of the mutants showed that these motifs are
required for Vif function in the virus and that function was
closely associated with hA3G degradation.
Finally, we tested a panel of polymorphic patient-derived
Vifs identified by Simon et al. (2005). The point mutations were
introduced into the codon-optimized Vif and tested in the
luciferase reporter virus assay (Fig. 7A, top). Of the six tested,
four were inactive while two (W11R and G143R) maintained
wild-type function, in agreement with the previous report
(Simon et al., 2005). Immunoblot analysis of the virions showed
that that the biologically inactive Vif mutants failed to prevent
the packaging of hA3G while W11R and G143R mutants did
not (Fig. 7A, bottom). In the cell lysates, there was no
significant difference in hA3G degradation between the active
(W11R and G413R) and inactive Vifs. In the α-complementa-
tion assay, W11R and G143RVifs were active, while the others
were inactive (Fig. 7B, top), in agreement with the luciferase
report virus assay. Immunoblot analysis of α-complementation
samples confirmed the hA3G-α degradation by active W11R
and G143R Vifs, but not other mutant Vifs (Fig. 7B, bottom).
The discrepancy between the α-complementation and the
reporter virus results was likely due to the difference in Vif:
hA3G ratio in the two assays. In the α-complementation assay,
the ratio was at 10:1 while in the luciferase reporter virus assay a
1:1 ratio was used. These results showed a close correlation of
Vif function in the viral infectivity with hA3G degradation,
supporting the importance of degradation for Vif function.
Discussion
We have developed a cell-based assay for Vif-induced
degradation of hA3G that is more rapid and accurate than
immunoblot analysis. The assay is dependent upon the
functional amino acid motifs of Vif including the Cul5-box,
BC-box and HCCH motif, and can be adapted to high-
throughput screening in small well formats. In principal,hA3G degradation could be measured by the more straight-
forward use of an hA3G-luciferase or hA3G-EGFP fusion
protein; however, initial tests of an hA3G-EGFP fusion protein
were unsuccessful (not shown). The fusion protein maintained
its antiviral activity but was insensitive to Vif, presumably as a
result of steric hindrance to Vif binding. The much smaller α-
peptide did not have this problem. In addition, our previous
findings demonstrated the high sensitivity of the α-comple-
mentation system (Holland et al., 2004).
In our current analysis of the D128K hA3G, a surprisingly
large proportion of the mutant protein was degraded by HIV-1
Fig. 6. The role of the BC-box, HCCH and Cul5-box in Vif-induced hA3G-α degradation. (A, top) 293T-ω cells were cotransfected with pA3G-α (0.3 μg) with
Vif BC box (S144, Q145 and L146) and HCCH (H108, C114, C133 and H139) mutant expression vectors (3 μg) and β-galactosidase activity was measured 2
days posttransfection. (A, middle) The effect of the Vif mutants on hA3G-α degradation was detected by immunoblot analysis of the transfected cell lysates.
(A, bottom) The effect of the Vif mutants on viral infectivity of Δvif virus was tested with luciferase reporter virus. (B, top, middle and bottom) Vif with
mutations in the Cul5-box (L163, P164 and L169) was similarly tested.
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probably the result of over-expression of Vif from the codon-
optimized expression vector. This result suggests that amino
acid 128 is not the sole determinant for the interaction with Vif.
The finding is consistent with our earlier report which showed
that the D128K hA3G could form a weak complex with Vif
(Schrofelbauer et al., 2004). The weak interaction is not
sufficient to fully induce hA3G degradation and as a result,
D128K hA3G scores as Vif-resistant in antiviral activity assays
(Bogerd et al., 2004; Mangeat et al., 2004; Schrofelbauer et al.,
2004; Xu et al., 2004).Most of the Vif mutants with alterations in the known
amino acid motifs were non-functional in the α-comple-
mentation assay, although one difference from published
results was noted. In contrast to previous reports, we found
that L145A Vif, which is altered at the highly conserved
SLQ motif, was active (Mehle et al., 2004a; Yu et al.,
2004). In our study, L145A rescued infectivity and induced
hA3G degradation. Alteration of the three amino acids of
the motif was needed to block Vif function. This difference
could be caused by the expression of high levels of Vif in
our system.
Fig. 7. Association of Vif function with hA3G degradation as determined using natural Vif point mutants from primary viruses. (A) Luciferase reporter viruses were
prepared in 293T cells cotransfected with 1 μg of wild-type or Δvif NL-LucR−E− and 1 μg of A3G-HA expression vector. Vif point mutant expression vectors (1 μg)
were included in the transfections and tested with luciferase reporter virus (top) and by immunoblot analysis (bottom). (B) 293T-ω cells were cotransfected with
pA3GQα (0.3 μg) and Vif point mutant expression vectors (3 μg) and were tested by α-complementation (top) and immunoblot analysis (bottom).
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Vif to rescue viral infectivity with hA3G degradation. Vif
mutants that were inactive failed to induce hA3G degradation
while functional mutants efficiently induced degradation. One
exception to this finding was the analysis of Vif mutants W11R
and G143R. At a 1:1 ratio of Vif to hA3G, W11R and G143R
Vif did not reduce hA3G levels in the cell. However, the
mutant Vifs restored viral infectivity and prevented hA3G
encapsidation, in agreement with a previous report (Tian et al.,
2006). At a 10:1 ratio, both mutants induced efficient hA3G
degradation. This could be interpreted as a dissociation of
hA3G degradation from biological function; however, an
alternative explanation is more likely. At reduced levels, Vif
may preferentially degrade hA3G molecules that are near
assembling virions in the cell. Vif is localized in the cell to
regions that contain Gag (Simon et al., 1997, 1999) and this
localization could be a means of catching hA3G molecules that
are in the proximity of an assembling virion. This would allow
Vif to block hA3G packaging without depleting hA3G from the
cell. With higher levels of Vif, hA3G might be depleted from
the cell. Our results are consistent with hA3G degradation as
the key mechanism for Vif function.
In a small molecule screen, the α-complementation assay
would detect cell permeable compounds that act either on Vif
or hA3G to block their interaction or compounds that inhibit
the E3 ligase or proteasome function. Small molecules that
target the protein degradation pathway could be cytotoxic by
interfering with the role of these proteins in cellular meta-
bolism. However, many of these proteins are redundant(Ciechanover, 2005; Schuberth et al., 2004) and their partial
inhibition might be sufficient to rescue the antiviral function of
hA3G. Thus, small molecules specific for Cul5/Elongin BC/
Rbx1 complexes might block Vif function without having
serious cytotoxic effects.
Current antiretrovirals target reverse transcriptase, protease
or envelope glycoprotein. The interaction of Vif with hA3G
is an additional promising target for drug development. The
αQcomplementation assay is rapid and accurate making it useful
for the discovery of molecules that target this interaction.
Materials and methods
Plasmids
pA3G-α was generated by amplification of a human A3G
cDNAwith primers containing XbaI and SmaI restriction sites.
The amplicon was digested with XbaI and SmaI and ligated to
similarly cleaved pcDNA3.1-α. To generate pcDNA3.1-α, the
DNA encoding the α-fragment was PCR amplified with primers
5′-GAGTCTAGAGTCGACCTGCAGCCCAAGCTTG-
GGCTG-3′ and 5′-GAGGGATCCCTCAGGAAGATCGCAC-
TCCAGCCAGCT-3′. The fragment was cleaved with XbaI and
BamHI and ligated to cleaved pcDNA3.1(−). phVif, pVif(co)
and pVif(co)-HA were described previously (Nguyen et al.,
2004; Schrofelbauer et al., 2006). phVifLF was constructed by
ligating a Vif fragment amplified from phVif with pcDNA3.1
(−). A3G and Vif mutants were generated using the Quick-
Change Site-Directed Mutagenesis Kit (Stratagene).
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293T, 293T-ω (Holland et al., 2004) and HOS cells were
maintained in DMEM/10% fetal bovine serum supplemented
with penicillin and streptomycin.
α-Complementation assay
293T or 293T-ω cells (5×105) were seeded in 6-well plates.
The next day, the cells were transfected using Lipofectamine
2000 (Invitrogen) with Vif and A3G expression vectors. After
48 h, the cells were rinsed twice with 2 ml cold phosphate
buffered saline (PBS), then scraped off the plates in 250 μl 1%
NP-40 lysis buffer. The lysates were incubated on ice for 30 min
and centrifuged at 14,000 rpm for 15 min at 4 °C. The protein
concentration of the supernatant was measured using coomassie
blue protein assay solution (Bio-Rad). Cell lysate containing
3 μg of protein was mixed with 100 μl of GalactoStar reagent
(Applied Biosystems) in a 96-well plate and incubated at room
temperature for 1 h. Luminescence was quantitated in triplicate
with a TopCount luminometer (Packard Instrument Co.). For
colorimetric measurement, 12 μg of cell lysate was mixed with
100 μl reaction buffer (0.32 mg/ml 2-Nitrophenyl β-D-
galactopyranoside (ONPG), 0.1 M phosphate buffer (pH 7.5))
and incubated at room temperature. The plate was read at A405
using a VersaMax microplate reader (Molecular Devices).
Luciferase reporter virus assay
293T cells were cotransfected with 1 μg of wild-type or Δvif
pNL-LucE−R− luciferase reporter virus plasmid (Connor et al.,
1995), 0.5 μg of pVSV-G, and with or without 1 μg of A3G
expression vector. For Vif mutant experiments, 1 μg of Vif
expression vector was also cotransfected. Reporter viruses were
harvested and the luciferase activity was measured as described
previously (Schrofelbauer et al., 2004).
Western blots
Cell lysate (10 μg) and solubilized virions (100 ng p24) were
separated by SDS-PAGE and transferred to PVDF membranes.
Proteins were detected with anti-human APOBEC3G mAb
(1:3000 dilution, Immunodiagnostic, Inc.), anti-HIV Vif mAb
(1:3000 dilution, AIDS Research and Reference Program), anti-
p24 mAb (1:500 dilution, AIDS Research and Reference
Program) and anti-tubulin mAb (1:5000, Sigma), as previously
described (Mariani et al., 2003; Schrofelbauer et al., 2004).
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